Table 1.
Patient characteristics and mutations at failure of second-line therapy.
| Variable | Median (inter quartile range) | ||
|---|---|---|---|
| Median (inter quartile range) | No PI major mutations (n = 70) | PI major mutations (n = 5) | |
| Age (years) | 34 (29–40) | ||
| CD4+ T-cells/mm3 | 141 (75–245) | 138 (80–229) | 246 (194–254) |
| HIV-1 RNA (copies/mL) | 184,779 (8790–166,300) | 61000 (15000–155000) | 3260 (2200–33000) |
| Time on second-line (months) | 16 (7–18) | ||
|
| |||
| Regimens | n | ||
| LPV/r, AZT, ddI | 53 | ||
| LPV/r, 3TC, AZT | 8 | ||
| LPV/r, 3TC, TNF | 4 | ||
| LPV/r, 3TC, ABC | 2 | ||
| LPV/r, AZT, d4T | 2 | ||
| LPV/r, ddI, TNF | 2 | ||
| LPV/r, 3TC, ddI | 1 | ||
| LPV/r, 3TC, EFV | 1 | ||
| LPV/r, AZT, EFV | 1 | ||
| LPV/r, FTC, TNF | 1 | ||
|
| |||
| Resistance Mutations | n (%) | ||
| NRTI mutations | 26 (35%) | ||
| M184V | 15 (20%) | ||
| K65R | 0 (0%) | ||
| Q151M | 1 (1%) | ||
| TAMs | 10 (13%) | ||
| NNRTI mutations | 39 (52%) | ||
| K103N | 16 (21%) | ||
| V106M | 9 (12%) | ||
| Any PR mutations (major and minor) | 67 (89%) | ||
| MajorLPV mutations | 5 (7%) | ||
| M46I, L76V | 1 | ||
| M46I | 1 | ||
| L33F, I54S, V82A, I84V | 1 | ||
| L33F, M46I, I54V, I84V, L90M | 1 | ||
| M46I, I54V, L76V | 1 | ||